GreenLight Biosciences (Nasdaq: ENVI), a US-based biotechnology company, and Samsung Biologics (KRX: 207940.KS), a Korea-based global CDMO offering completely integrated end-to-end contract development and manufacturing services, announced on Wednesday that they have entered into a collaboration agreement for the production of GreenLight's messenger RNA COVID-19 vaccine candidate at commercial scale.

The collaboration intends to expedite production of GreenLight's COVID-19 vaccine candidate for Phase III clinical trials and is subject to regulatory approval for commercial sales. It will use GreenLight's present manufacturing process, with technology transfer from GreenLight Biosciences to Samsung Biologics commencing immediately.

GreenLight CEO Andrey Zarur, said, 'We are delighted to partner with Samsung to manufacture messenger RNA for our Covid vaccine trial. There is an urgent need to develop vaccines for the whole world. Our vaccine trial will open the way to make vaccines that are available to everybody, not just citizens of developed countries.'